CNSX:BLO

Cannabix Technologies Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume188,592 shs
Average Volume301,179 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cannabix Technologies (CNSX:BLO) Vs. WEED, LEAF, OGI, EMC, ICC, and CMED

Should you be buying BLO stock or one of its competitors? Companies in the sub-industry of "cannabis" are considered alternatives and competitors to Cannabix Technologies, including Canopy Growth (WEED), Leaf Mobile (LEAF), OrganiGram (OGI), Emblem (EMC), ICC Labs (ICC), and (CMED.TO) (CMED).

Cannabix Technologies (CNSX:BLO) and Canopy Growth (TSE:WEED) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Cannabix Technologies and Canopy Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabix TechnologiesN/AN/AN/A
Canopy GrowthN/AN/AN/A

Valuation & Earnings

This table compares Cannabix Technologies and Canopy Growth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabix TechnologiesN/AN/AN/AN/AN/A
Canopy GrowthC$506.12 million26.26C$-2,459,879,050.00C($6.43)-5.40

Cannabix Technologies has higher earnings, but lower revenue than Canopy Growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cannabix Technologies and Canopy Growth, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabix Technologies0000N/A
Canopy Growth44001.50

Canopy Growth has a consensus target price of C$38.46, indicating a potential upside of 11.88%.

Summary

Canopy Growth beats Cannabix Technologies on 1 of the 1 factors compared between the two stocks.

Leaf Mobile (TSE:LEAF) and Cannabix Technologies (CNSX:BLO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Leaf Mobile and Cannabix Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Leaf Mobile00103.00
Cannabix Technologies0000N/A

Leaf Mobile presently has a consensus target price of C$0.75, indicating a potential upside of 94.81%.

Valuation and Earnings

This table compares Leaf Mobile and Cannabix Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leaf MobileC$19.24 million15.30C$-4,586,262.00C($0.01)-64.17
Cannabix TechnologiesN/AN/AN/AN/AN/A

Cannabix Technologies has lower revenue, but higher earnings than Leaf Mobile.

Profitability

This table compares Leaf Mobile and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Leaf MobileN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

Leaf Mobile beats Cannabix Technologies on 2 of the 2 factors compared between the two stocks.

OrganiGram (TSE:OGI) and Cannabix Technologies (CNSX:BLO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for OrganiGram and Cannabix Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OrganiGram42201.75
Cannabix Technologies0000N/A

OrganiGram presently has a consensus target price of C$3.77, indicating a potential upside of 19.24%.

Valuation and Earnings

This table compares OrganiGram and Cannabix Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrganiGramC$80.97 million11.56C$-274,672,593.00C($0.92)-3.41
Cannabix TechnologiesN/AN/AN/AN/AN/A

Cannabix Technologies has lower revenue, but higher earnings than OrganiGram.

Profitability

This table compares OrganiGram and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganiGramN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

OrganiGram beats Cannabix Technologies on 2 of the 2 factors compared between the two stocks.

Emblem (CVE:EMC) and Cannabix Technologies (CNSX:BLO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Emblem and Cannabix Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emblem0000N/A
Cannabix Technologies0000N/A

Valuation and Earnings

This table compares Emblem and Cannabix Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emblem$5.71 million43.02C$-24,806,020.00($0.19)-9.89
Cannabix TechnologiesN/AN/AN/AN/AN/A

Cannabix Technologies has lower revenue, but higher earnings than Emblem.

Profitability

This table compares Emblem and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EmblemN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

Emblem beats Cannabix Technologies on 1 of the 1 factors compared between the two stocks.

ICC Labs (CVE:ICC) and Cannabix Technologies (CNSX:BLO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Earnings & Valuation

This table compares ICC Labs and Cannabix Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICC LabsC$533,684.00419.04C$2.35 millionC$0.0295.29
Cannabix TechnologiesN/AN/AN/AN/AN/A

ICC Labs has higher revenue and earnings than Cannabix Technologies.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ICC Labs and Cannabix Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICC Labs0000N/A
Cannabix Technologies0000N/A

Profitability

This table compares ICC Labs and Cannabix Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICC LabsN/AN/AN/A
Cannabix TechnologiesN/AN/AN/A

Summary

ICC Labs beats Cannabix Technologies on 1 of the 1 factors compared between the two stocks.

Cannabix Technologies (CNSX:BLO) and (CMED.TO) (TSE:CMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Valuation and Earnings

This table compares Cannabix Technologies and (CMED.TO)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cannabix TechnologiesN/AN/AN/AN/AN/A
(CMED.TO)N/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cannabix Technologies and (CMED.TO), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cannabix Technologies0000N/A
(CMED.TO)0000N/A

Profitability

This table compares Cannabix Technologies and (CMED.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cannabix TechnologiesN/AN/AN/A
(CMED.TO)N/AN/AN/A


Cannabix Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
WEED
Canopy Growth
1.1$34.76flatC$13.29 billionC$506.12 million-5.40
Leaf Mobile logo
LEAF
Leaf Mobile
1.2$0.39flatC$2.47 billionC$19.24 million-64.17Gap Down
OrganiGram logo
OGI
OrganiGram
1.2$3.14flatC$936.45 millionC$80.97 million-3.41Earnings Announcement
Analyst Report
Analyst Revision
EMC
Emblem
0.5$1.88flat$248.31 million$5.71 million-9.89
ICC
ICC Labs
0.5$1.62flatC$228.24 millionC$533,684.0095.29Gap Down
CMED
(CMED.TO)
0.6N/AN/AC$0.00N/A0.00
MJN
(MJN.V)
0.5$12.15flatC$0.00N/A0.00
SL
(SL)
0.6N/AN/AC$0.00N/A0.00High Trading Volume
Gap Up
BE
Beleave
0.6N/AN/AC$0.00N/A0.00High Trading Volume
BE
Beleave
0.6N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
MGW
Maple Leaf Green World
0.6$0.79flatC$0.00N/A0.00Gap Down
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.